# US 5,348,741 A · Vector for recombinant poxvirus expressing rabies virus glycoprotein > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,348,741 A - Document ID: US5348741A - Status: Granted - Kind: A - Application number: 07/944,743 - Filed: 1992-09-14 - Granted: 1994-09-20 - Earliest claimed: 1987-02-03 - Assignees: The United States of America as represented by the Department of Health and Human Services - Inventors: Joseph J. Esposito; Bernard Moss; Kathleen Brechling - Web page: https://patentgrep.com/patent/US5348741A ## CPC - C12N 15/86: Viral vectors - C07K 14/005: from viruses - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - C07K 2319/00: Fusion polypeptide - C12N 2710/24143: viral genome or elements thereof as genetic vector - C12N 2760/20122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A plasmid vector has been constructed for producing unique vaccinia virus recombinant expressing the gene for rabiesvirus glycoprotein in cells. The recombinant induces production of glycoprotein in substantial amounts for immunization against rabies. Such recombinant could be applied for the production of anti-rabies vaccine and of G antigen antibody and related immunological reagents for research or diagnostic purposes. ## Claims ### Claim 1 A plasmid having recombinant DNA comprising a rabies virus glycoprotein G gene operatively linked to a vaccinia P.sub.11 late promoter. ### Claim 2 (depends on 1) The plasmid of claim 1 wherein the rabies virus glycoprotein G gene is from Challenge Virus Standard strain. ### Claim 3 (depends on 1) The plasmid of claim 1 having all the identifying characteristics of ATCC 40280. ### Claim 4 A poxvirus recombinant having incorporated therein a rabies virus glycoprotein G gene operatively linked to a vaccinia P.sub.11 late promoter. ### Claim 5 (depends on 4) The poxvirus of claim 4 wherein said poxvirus is the New York City Board of health strain of Vaccinia virus. ### Claim 6 (depends on 4) A pharmaceutical composition comprising an immunogenic amount of the recombinant of claims 4 in a pharmaceutically acceptable carrier. ### Claim 7 (depends on 4) A method of inducing protective immunity against rabiesvirus infection in a host comprising administering to a host, susceptible to rabiesvirus infection, an immunogenic amount of recombinant of claim 4 to produce protective immunity against rabiesvirus in said host. ### Claim 8 (depends on 4) The poxvirus of claim 4, wherein said poxvirus is an orthopoxvirus. ### Claim 9 (depends on 8) The poxvirus of claim 8, wherein said orthopoxvirus is cowpox virus. ### Claim 10 (depends on 4) The poxvirus of claim 4, wherein said gene and said promoter are inserted into the TK locus of said poxvirus. ### Claim 11 (depends on 4) The poxvirus recombinant of claim 4, which, when infected into cell culture, expresses both completely glycosylated and incompletely glycosylated forms of said glycoprotein. ### Claim 12 (depends on 4) The poxvirus of claim 4, wherein the DNA sequence coding for glycoprotein G is precisely placed at the 11 kd protein translation start site to thereby retain a naturally occurring vaccinia leader. ### Claim 13 (depends on 4) The poxvirus of claim 4, which is vKB3-JE-8. ### Claim 14 (depends on 4) The poxvirus of claim 4, which is vKB3-JE-13. ### Claim 15 (depends on 4) The poxvirus of claim 4, which is vKB36. ### Claim 16 An NYBH strain poxvirus recombinant capable of expressing rabies virus glycoprotein G from Challenge Virus Standard Strain under control of promoter P.sub.11. ### Claim 17 (depends on 4) A method for inducing protective immunity against rabies virus infection in a mammal comprising administering to a mammal, susceptible to rabies an effective amount of the poxvirus recombinant of claim 4, under conditions which allow said poxvirus to infect said mammal and express glycoprotein G under control of said promoter. ### Claim 18 (depends on 17) The method of claim 17, wherein said poxvirus is vKB3-JE-13. ### Claim 19 (depends on 4) The poxvirus of claim 4, comprising a poxvirus P.sub.11 promoter positioned upstream of a gene for the precursor of the mature glycoprotein G of rabies virus by a short intervening sequence of DNA, wherein said intervening sequence provides an ATG codon sufficient for translational initiation and additional nucleotide residues such that the precursor gene remains in the proper translational reading frame with respect to the translational initiator codon and retains the coding sequences of the precursor protein required for proper intracellular processing, such that the mature glycoprotein G is obtained upon expression of the precursor gene in cells infected with said poxvirus. ### Claim 20 (depends on 8) A composition of matter comprising a recombinant poxvirus of claim 8 in a pharmaceutical carrier.